Alfonso J. Tafur: New Biomarkers Transform Pulmonary Embolism Risk Prediction
Alfonso J. Tafur, Board Member VAS European Independent Foundation in Angiology and Vasculearn Network, shared RPTH Journal’s post on LinedIn about a recent article he and his colleagues co-authored, adding:
“Proud to be a co-author on this important publication led by Fakiha Siddiqui Congratulations
This study moves beyond traditional clinical risk scores by showing that thromboin flammation and hemostatic activation are major drivers of early mortality in acute PE. Among the most clinically relevant findings:
- Neutrophil-to-lymphocyte ratio (NLR) above 7 emerged as one of the strongest and most accessible predictors of 30-day mortality.
- Combining NLR, PAI-1, and TNF-α identified a subgroup with markedly higher mortality, highlighting the value of integrated biomarker assessment.
- The work supports incorporating biologic markers of inflammation, endothelial injury, coagulation, and fibrinolysis into future PE risk stratification models. Precision Medicine
Excited to see how these findings help shape the next generation of personalized pulmonary embolism care.”
RPTH Journal shared a post on LinkedIn:
“Pulmonary embolism mortality: can thromboinflammation biomarkers do better than current scoring systems?
Despite advances in diagnosis and treatment, pulmonary embolism (PE) still carries significant mortality, and current prognostic models remain poorly predictive of who will deteriorate. A new study in RPTH Journal takes a comprehensive biomarker approach to address this gap.
Key findings from 500 patients with PE (9.7% died within 30 days):
- Levels of vWF, P-selectin, tissue factor, tPA, PAI-1, D-dimer, CRP, IL-6, TNF-α, NLR, PLR, and SII were significantly higher in 30-day non-survivors
- FVII, FX, FXIIIA, and TAFI levels were significantly lower in non-survivors
- Multivariable analysis confirmed independent associations between these markers and 30-day mortality
- CHAID recursive partitioning identified NLR, PAI-1, and TNF-α as the key mortality predictors, with quantifiable thresholds established for each.”
Title: Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolism
Authors: Fakiha Siddiqui, Alfonso Tafur, Amir Darki, Bulent Kantarcioglu, Debra Hoppensteadt, Jeanine Walenga, Manuel Monreal, Jawed Fareed

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 9, 2026, 10:06Care Shouldn’t Depend on Where You Live – National Bleeding Disorders Foundation
-
Aug 9, 2026, 10:01Irma Bagdoniene: Plaque Stability and the Importance of LDL Lowering
-
Aug 9, 2026, 09:49Rana Al-Dhalaan: New Study Examines Viral Infections in Blood Donors
-
Aug 9, 2026, 09:29Michael Wilkinson: How Lp(a) Shapes Coronary Plaque and Cardiovascular Risk
-
Aug 9, 2026, 09:16Preparing for Gene Therapy Starts with Understanding Immunity – WFH
-
Aug 9, 2026, 08:46Christina Pohlman: Uncovering the Autoantibodies Behind APS
-
Aug 9, 2026, 08:39Alejandro González Veliz: The Future of Cardiogenic Shock Lies in Precision Medicine
-
Aug 9, 2026, 08:29Heba Youssef: Off-Label Doesn’t Mean Off-Guidelines
-
Aug 9, 2026, 08:18Fawaz AlOtaibi: Why Experts Are Challenging the New Stroke Guideline